drugset / Trial / NCT05343481
Efficacy of VTP-300 in Chronic Hepatitis B Infection
RandomizedSequentialOpen-labelTreatment
Summary
This is an open-label study to determine the efficacy, safety, tolerability and immunogenicity of ChAdOx1-HBV and MVA-HBV, together VTP-300, in combination with low-dose nivolumab, in patients with chronic HBV who are virally suppressed with oral anti-viral therapies.
Timeline
- Start
- 2022-09-21
- Primary completion
- 2026-01-13
- Completion
- 2026-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ChAdOx1-HBV | Vaccine | 2.5e+10 unknown | Intramuscular |
| Subject | MVA-HBV | Vaccine | 1e+08 unknown | Intramuscular |
| Subject | Nivolumab | Monoclonal antibody | 0.3 mg/kg | Intravenous |